Endothelin antagonist as add-on treatment for proteinuria in diabetic nephropathy: Is there light at the end of the tunnel?

Journal of the American Society of Nephrology

Volumn 22, Issue 4, 2011, Pages 593-595

  Ritz, Eberhard ^a   Wenzel, René R ^b  

^a Nierenzentrum   (Germany)

^b Paracelsus University Salzburg (Austria)   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ATRASENTAN; AVOSENTAN; BOSENTAN; DARUSENTAN; DIURETIC AGENT; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN B1 RECEPTOR; ENDOTHELIN B2 RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; LISINOPRIL; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ADD ON THERAPY; ANTIHYPERTENSIVE ACTIVITY; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; EDEMA; EDITORIAL; FLUID RETENTION; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; NONHUMAN; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROSTATE CANCER; PROTEINURIA; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIDE EFFECT; SODIUM RESTRICTION; SODIUM RETENTION; UNSPECIFIED SIDE EFFECT;

EID: 79953301153     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2011020158     Document Type: Editorial

References (19)

1. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332: 411-415, 1988 (Pubitemid 18090241)
2. Ahn D, Ge Y, Stricklett PK, Gill P, Taylor D, Hughes AK, Yanagisawa M, Miller L, Nelson RD, Kohan DE: Collecting duct-specific knockout of endothelin-1 causes hypertension and sodium retention. J Clin Invest 114: 504-511, 2004 (Pubitemid 39572100)
3. Pavlov TS, Chahdi A, Ilatovskaya DV, Levchenko V, Vandewalle A, Pochynyuk O, Sorokin A, Staruschenko A: Endothelin-1 inhibits the epithelial Na+ channel through betaPix/14-3-3/Nedd4-2. J Am Soc Nephrol 21: 833-843, 2010
4. Ge Y, Bagnall A, Stricklett PK, Strait K, Webb DJ, Kotelevtsev Y, Kohan DE: Collecting duct-specific knockout of the endothelin B receptor causes hypertension and sodium retention. Am J Physiol Renal Physiol 291: F1274-F1280, 2006 (Pubitemid 44889187)
5. Packer M, McMurray J, Massie BM, Caspi A, Charlon V, Cohen-Solal A, Kiowski W, Kostuk W, Krum H, Levine B, Rizzon P, Soler J, Swedberg K, Anderson S, Demets DL: Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: Results of a pilot study. J Card Fail 11: 12-20, 2005 (Pubitemid 40215308)
6. Anand I, McMurray J, Cohn JN, Konstam MA, Notter T, Quitzau K, Ruschitzka F, Luscher TF: Long-term effects of darusentan on left-ventricular remodeling and clinical outcomes in the Endothelin A Receptor Antagonist Trial in Heart Failure (EARTH): Randomised, double-blind, placebo-controlled trial. Lancet 364: 347-354, 2004 (Pubitemid 38970011)
7. Schildroth J, Rettig-Zimmermann J, Kalk P, Steege A, Fahling M, Sendeski M, Paliege A, Lai EY, Bachmann S, Persson PB, Hocher B, Patzak A: Endothelin type A and B receptors in the control of afferent and efferent arterioles in mice. Nephrol Dial Transplant September 2, 2010 [epub ahead of print]
8. Ong AC, Jowett TP, Firth JD, Burton S, Karet FE, Fine LG: An endothelin-1 mediated autocrine growth loop involved in human renal tubular regeneration. Kidney Int 48: 390-401, 1995
9. Wenzel RR, Littke T, Kuranoff S, Jurgens C, Bruck H, Ritz E, Philipp T, Mitchell A: Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol 20: 655-664, 2009
10. Mann JF, Green D, Jamerson K, Ruilope LM, Kuranoff SJ, Littke T, Viberti G: Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 21: 527-535, 2010
11. Kohan DE, Pritchett Y, Molitch M, Wen S, Garimella T, Audhya P, Andress DL: Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. J Am Soc Nephrol 22: 763-772, 2011
12. Kohan DE: Biology of endothelin receptors in the collecting duct. Kidney Int 76: 481-486, 2009
13. Weber MA, Black H, Bakris G, Krum H, Linas S, Weiss R, Linseman JV, Wiens BL, Warren MS, Lindholm LH: A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: A randomised, double-blind, placebo-controlled trial. Lancet 374: 1423-1431, 2009
14. Shiigai T, Shichiri M: Late escape from the antiproteinuric effect of ACE inhibitors in nondiabetic renal disease. Am J Kidney Dis 37: 477-483, 2001 (Pubitemid 32195285)
15. Sato A, Hayashi K, Saruta T: Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens 18: 44-49, 2005 (Pubitemid 40187348)
16. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK: Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 358: 2433-2446, 2008 (Pubitemid 351793017)
17. de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, Parving HH, Pritchett Y, Remuzzi G, Ritz E, Andress D: Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): A randomised controlled trial. Lancet 376: 1543-1551, 2010
18. Zonnenberg BA, Groenewegen G, Janus TJ, Leahy TW, Humerickhouse RA, Isaacson JD, Carr RA, Voest E: Phase I dose-escalation study of the safety and pharmacokinetics of atrasentan: An endothelin receptor antagonist for refractory prostate cancer. Clin Cancer Res 9: 2965-2972, 2003 (Pubitemid 37006310)
19. Gagliardini E, Corna D, Zoja C, Sangalli F, Carrara F, Rossi M, Conti S, Rottoli D, Longaretti L, Remuzzi A, Remuzzi G, Benigni A: Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes. Am J Physiol Renal Physiol 297: F1448-F1456, 2009